Phase 2 Study of Dabrafenib Plus Trametinib in Patients With BRAF V600E-Mutant Metastatic NSCLC: Updated 5-Year Survival Rates and Genomic Analysis
David Planchard, Benjamin Besse, Harry J.M. Groen, Sayed M.S. Hashemi, Julien Mazières, Tae Min Kim, Élisabeth Quoix, Pierre‐Jean Souquet, Fabrice Barlési, Christina S. Baik, Liza C. Villaruz, Ronan J. Kelly, Shirong Zhang, Monique Tan, Eduard Gasal, Libero Santarpia, Bruce E. Johnson
Topics & Concepts
DabrafenibMedicineTrametinibInternal medicineCohortConfidence intervalOncologyClinical endpointProgression-free survivalAdverse effectOverall survivalClinical trialMetastatic melanomaVemurafenibCancerMAPK/ERK pathwayCell biologyBiologyKinaseMelanoma and MAPK PathwaysLung Cancer Treatments and MutationsCancer Mechanisms and Therapy